Boston Therapeutics Inc (BTHE) financial statements (2020 and earlier)

Company profile

Business Address 354 MERRIMACK STREET
LAWRENCE, MA 01843
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments912137687411573,387
Cash and cash equivalents912137687411573,387
Receivables0015  100
Inventory, net of allowances, customer advances and progress billings613955110198111
Inventory613955110198111
Prepaid expense    7889154
Other undisclosed current assets32490821583   
Total current assets:3399223918302294453,752
Noncurrent Assets
Property, plant and equipment124281415
Intangible assets, net (including goodwill)402515509573638702766
Goodwill  7070707070
Intangible assets, net (excluding goodwill)402515439504568632696
Other undisclosed noncurrent assets    422
Total noncurrent assets:403517513575649718784
TOTAL ASSETS:7431,4399041,4058781,1634,535
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2,2861,670652667853772955
Accounts payable592510299319575411171
Accrued liabilities1,6941,161353347278278721
Interest and dividends payable     8363
Debt7004501,207    
Derivative instruments and hedges, liabilities254429    
Due to related parties1,59975827829820  
Other liabilities     6356
Other undisclosed current liabilities1,7741,7261,122112164(44)(119)
Total current liabilities:6,3624,6593,6881,0771,038791892
Noncurrent Liabilities
Long-term debt and lease obligation   36593  
Long-term debt, excluding current maturities   36593  
Liabilities, other than long-term debt    278298298
Due to related parties    278298298
Other undisclosed noncurrent liabilities 9261,0993,082   
Total noncurrent liabilities: 9261,0993,447371298298
Total liabilities:6,3625,5854,7874,5241,4091,0881,190
Stockholders' equity
Stockholders' equity attributable to parent, including:(5,619)(4,146)(3,884)(3,119)(531)753,345
Preferred stock 00    
Common stock1111106447393937
Additional paid in capital19,21919,15615,86315,06113,71912,03510,607
Accumulated deficit(24,949)(23,412)(19,811)(18,226)(14,489)(11,999) 
Other undisclosed stockholders' equity attributable to parent0   200 (7,299)
Total stockholders' equity:(5,619)(4,146)(3,884)(3,119)(531)753,345
TOTAL LIABILITIES AND EQUITY:7431,4399041,4058781,1634,535

Income statement (P&L) ($ in thousands)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Revenues2032299999200323
Revenue, net7 70182 
Cost of revenue47(32)(13)(94)(240)(176)(278)
Cost of goods and services sold (32)(13)(94)(240)(176)(278)
Gross profit:66(0)165(142)2445
Operating expenses(3,810)(3,311)(1,295)(1,269)(1,960)(4,698)(4,625)
Other undisclosed operating income (loss)(47)3213    
Operating loss:(3,791)(3,279)(1,266)(1,264)(2,101)(4,674)(4,580)
Nonoperating income (expense)   (402)(4)(6)2
Other nonoperating income (expense)   (402)(4)(5)2
Interest and debt expense4572(1,738)(1,943)(311)(20)(20)
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes306(324)1,419(125)   
Loss from continuing operations before income taxes:(3,028)(3,601)(1,585)(3,734)(2,416)(4,700)(4,598)
Income tax expense   (4)   
Loss before gain (loss) on sale of properties:(3,028)(3,601)(1,585)(3,738)(2,416)(4,700)(4,598)
Other undisclosed net loss    (73) (3)
Net loss available to common stockholders, diluted:(3,028)(3,601)(1,585)(3,738)(2,490)(4,700)(4,602)

Comprehensive Income ($ in thousands)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss:(3,028)(3,601)(1,585)(3,738)(2,490)(4,700)(4,602)
Comprehensive loss, net of tax, attributable to parent:(3,028)(3,601)(1,585)(3,738)(2,490)(4,700)(4,602)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: